CL
RXRX icon

Choreo LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Choreo LLC’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.2K Sell
10,132
-148
-1% -$493 ﹤0.01% 1649
2026
Q1 		$31.6K Buy
+10,280
New +$39.7K ﹤0.01% 1586

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Choreo LLC's RXRX Position: Q2 2026 in Review

Choreo LLC reduced its Recursion Pharmaceuticals (RXRX) stake by 1.4% in Q2 2026, selling an estimated $493 and leaving 10,132 shares worth $37.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1649.

Choreo LLC first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Choreo LLC held 10,132 shares of Recursion Pharmaceuticals worth $37.2K as of Q2 2026.
  • Choreo LLC sold 148 Recursion Pharmaceuticals shares in Q2 2026, an estimated $493.
  • Recursion Pharmaceuticals made up ﹤0.01% of Choreo LLC's portfolio in Q2 2026, its #1649 holding.
  • Choreo LLC first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.